Astonea Labs H1FY27: consol PAT +149% YoY to ₹4.74 Cr, margins expand, revenue +45%

Astonea Labs' H1 FY27 (half year ended 30 Sept 2026) consolidated revenue rose 44.6% YoY to ₹95.86 Cr (H1 FY26: ₹66.29 Cr) and consolidated PAT rose ~149% YoY to ₹4.74 Cr (H1 FY26: ₹1.90 Cr). The print carries a ₹46.16 Lakh exceptional item — the uninsured portion of inventory destroyed in an April 27, 2026 factory fire — so reported PAT growth actually understates the underlying trend: adjusting for that one-off, PAT growth is ~173% YoY. Margins expanded alongside the growth: consolidated net profit margin moved to ~4.9% from ~2.9%, and EBITDA margin (profit before exceptional items/tax plus finance costs and depreciation, net of other income) widened to ~13.4% from ~8.1% a year earlier, pointing to operating leverage rather than one-off gains driving the improvement. There is no analyst coverage of the stock (zero analysts tracked per Simply Wall St), so a street-estimate comparison isn't possible. Against management's own FY27 guidance of ₹215-230 Cr revenue (45-55% YoY growth, disclosed in its FY26 results commentary), H1's 44.6% YoY growth sits right at the floor of that range — on track, but H2 revenue would need to step up to roughly ₹119-134 Cr from H1's ₹95.86 Cr to clear the guided band, a meaningfully higher run-rate than H1 delivered. Management had separately flagged FY26 profit pressure from 'strategic investments in distribution, branding and regulatory infrastructure' with margin recovery expected in FY27; this half's margin expansion is consistent with that framing, though the fire loss is a fresh, unguided drag the company will need to absorb. The same board meeting approved a ₹12 Cr annual related-party transaction ceiling with newly incorporated Longevity Science Pvt Ltd, in which Astonea is subscribing to a 51% stake — a forward expansion step that has no P&L impact yet since incorporation (Oct 8, 2026) falls after the reporting half.